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Background: Osteoporosis results with the imbalance between osteoblastic for-
mation and osteoclastic resorption, resulting in susceptibility to bone fractures. 
Ovariectomy leads to osteoporosis by triggering alterations in bone formation and 
structure. Tamoxifen as an anti-oestrogen is used for adjuvant therapy especially 
in metastatic diseases and known to have a bone mass protective effect after 
ovariectomy. 
Materials and methods: An animal model of ovariectomy induced osteoporosis 
after tamoxifen citrate administration was studied via biochemical and immuno-
histochemical methods. Female Wistar albino rats (n = 45), selected according 
to their oestrous cycle, were divided into three groups; I — control, II — ovariec-
tomy, III — ovariectomy + tamoxifen. Following ovariectomy, tamoxifen citrate 
(10 mg/kg) was given intraperitoneally daily for 8 weeks. At the end of the 
period, animals were sacrificed under anaesthesia, blood samples were taken to 
measure oestrogen, calcium, and alkaline phosphate. Tibia bone samples were 
fixed in formalin solution and decalcified with 5% ethylene-diamine tetra acetic 
acid. After the routine histological follow up, samples were embedded in paraffin 
and cut with a microtome for semi-thin sections. Primary antibodies osteonectin 
and osteopontin were applied to sections and examined under light microscope. 
Results: As a consequence, when oestrogen and calcium data were compared 
there was a decrease in ovariectomy group with an increase in alkaline phos-
phatase. In ovariectomy + tamoxifen group, these values were close to the control 
group. Osteonectin was observed to promote bone formation by influencing col-
lagen fibre formation, extracellular matrix development, osteoblast differentiation 
and the capacity to affect osteoclast activity. 
Conclusions: It has been suggested that osteopontin, the cytokine and cell binding 
protein, stimulates cellular signalling pathways, induces bone remodelling and 
acts in osteoporosis. (Folia Morphol 2019; 78; 4: 789–797)
Key words: ovariectomy, bone remodelling, tamoxifen, osteonectin, 
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INTRODUCTION
Ovariectomy (OVX) is a procedure to simulate the 
hormonal status of postmenopausal women. Osteo-
porosis is a multifaceted skeletal disease characterised 
by decreased bone mass and impaired structure of 
the bone tissue, resulting in mechanical strength loss 
and increased fracture risk [11]. Bone resorption after 
ovariectomy leads to bone loss, initially exceeding 
bone formation. Shortly after this, bone remodelling 
reaches a steady state where absorption and forma-
tion are balanced [23]. Depending on the severity of 
the oestrogen deficiency, post-menopausal women 
can experience a reduction in osteoblastic activity in 
the bones and bone matrix, as well as a decrease in 
calcium and phosphate accumulation in the bones. 
Tamoxifen is a well characterised breast cancer 
drug and prophylactic that is a selective oestrogen 
receptor modulator (SERM). SERMs are structural-
ly diverse compounds that bind the oestrogen re-
ceptor and elicit ligand- and tissue-specific effects. 
Tamoxifen demonstrates the ability of oestrogen to 
increase bone mass and reduce the risk of fracture 
in postmenopausal women. However, it functions 
as an oestrogen antagonist in reproductive tissues 
[13, 15]. SERMs may share the stimulatory effect of 
oestrogen on osteoblast activity and are therefore 
reported to provide an alternative basis for anabolic 
treatment in osteoporosis. Experimental studies on 
rats depicted that tamoxifen may have a bone mass 
protective effect after ovariectomy [12]. Tamoxifen is 
a commonly used anti-oestrogen for adjuvant therapy 
and metastatic disease in postmenopausal women 
with breast cancer having a high risk of osteoporosis. 
Tamoxifen has been shown to induce the longitudinal 
growth rate in connection with an increase in the 
width of the proliferation zone in the bone epiphyseal 
plate. However, oestrogen was indicated to suppress 
the rate of longitudinal growth [30]. Tamoxifen has 
been shown to inhibit prostaglandin synthesis in vitro 
[41], and it was previously reported that prostaglan-
din E, a potent bone resorbing agent, increases in 
bone after immobilisation [42]. Tamoxifen has also 
been shown to regulate the expression of genes that 
control polyamine biosynthesis [36], and polyamine 
inhibitors have been shown to inhibit parathyroid 
hormone-mediated bone resorption [26]. Induction 
of transforming growth factor-beta by tamoxifen 
has also been reported [20]. Transforming growth 
factor-beta is believed to play an important role in 
intercellular communication within bone [27].
Osteonectin is a glycoprotein abundantly ex-
pressed in bone undergoing active remodelling os-
teonectin is synthesised by cells of the osteoblastic 
lineage; binds hydroxyapatite, calcium, and type I 
collagen; and inhibits mineralisation in vitro [19]. 
Osteopontin (OPN) is one of the major non-collagen 
proteins in extracellular bone matrix; it has a role in 
osteoclast-mediated bone resorption [21]. OPN is pro-
duced by differentiated osteoblasts and osteocytes, 
and also by osteoclasts. OPN has resorptive activ-
ity with the formation, migration and attachment 
of osteoclasts [33]. During bone remodelling, bone 
cells secrete OPN physiologically. It was noted that 
OPN acts as a pro-inflammatory cytokine and plays 
an important role in regulating the inflammatory 
process [34].
The aim of this study was to investigate the ex-
pressions of osteonectin and osteopontin proteins in 
tamoxifen citrate administrated in OVX rats.
MATERIALS AND METHODS
Animals
Every single surgical methodology and the con-
sequent care and healing of the animals utilised 
as a part of this investigation was in strict under-
standing with the National Institutes of Health (NIH 
Publications No. 85-23) rules for animal care. The 
Experimental Animal Laboratory Institute of Dicle 
University supplied 45 healthy adult female Wistar 
rats (280–310 g), which were selected according 
to their oestrous cycle. This study was approved by 
the Ethics Committee for Animal Experimentation of 
the Faculty of Medicine at Dicle University, Turkey. 
The rats were housed in separate cages at 26 ± 2°C 
with 40–60% humidity and were exposed to 10–12 h 
of daylight. They were fed a standard laboratory 
diet and tap water ad libitum. All rats at the end of 
experiment were healthy and no difference in food/
water consumption and body weight gain between 
experimental and control rats were observed.
Experimental procedure
Three groups (15 rats per group) were arranged 
as below:
 — Control group: animals were fed only standard 
rat chow and drinking water for 8 weeks;
 — Ovariectomy group: prior to surgery, the abdom-
inal areas of the rats were cleaned and removed 
from the ovarian cervical horns by making a 2 cm 
incision. The bilateral ovaries were removed from 
791
M. Baloğlu, E. Gökalp Özkorkmaz, Tamoxifen citrate administration in ovariectomized rats
the uterine apex with silk thread. The ovariectomy 
was performed with two dorsolateral incisions 
according to the method by Park et al. [29]. The 
uterus was left in the abdominal cavity, and the 
abdominal area was closed with a sterile suture;
 — Ovariectomy + tamoxifen group: Following the 
bilateral ovariectomy, the animals were given in-
traperitoneally 10 mg/kg/day tamoxifen citrate 
for 8 weeks.
All animals were anesthetised using 50 mg/kg of 
Ketalar® Vial M (ketamine HCl-Pfizer) and 10 mg/kg 
Rompun 25 mL 2% w/v solution for intramuscular 
injection (xylazine hydrochloride; Bayer). Blood sam-
ples were taken for oestrogen, calcium, and alkaline 
phosphate levels. Then, the tibia bones were dissected 
bilaterally for the basic histology and immunohisto-
chemistry. 
Histopathological evaluation 
The tibial bone samples were fixed with 10% neu-
tral buffered formalin solution and decalcified with 
5% ethylenedaiminetetraacetic acid (EDTA). After 
preservation, the tibial bone samples were directly 
dehydrated in a graded series of ethanol and em-
bedded in paraffin wax. Next, 4–6 µm sections of 
the tibia bones were cut with a microtome (Rotatory 
Microtome, Leica, RM 2265, Germany) and mounted 
on coated slides. Bone sections were stained with 
haematoxylin and eosin (H&E) for observation by light 
microscopy (Nikon Eclipse 80i).
Biochemical analysis
Serum calcium, oestrogen and serum alkaline 
phosphatase (ALP) levels were measured using stand-
ard colorimetric methods with commercial kits (Sigma 
Chemical Co., Saint Louis, MA).
Immunohistochemical staining 
Sections were brought to distilled water and 
washed in 3 × 5 min phosphate buffered saline (PBS) 
(Catalogue number 10010023, Thermo Fischer Scien-
tific Fremont, CA, USA). Antigen retrieval was done 
in microwave (Bosch®, 700 watt) for 3 min × 90oC. 
They were subjected to a heating process in a mi-
crowave oven at 700 watts in a citrate buffer (pH 6) 
solution for proteolysis. Sections were washed in 
3 × 5 min PBS and incubated with hydrogen perox-
ide [K-40677109, 64271 Hydrogen peroxide (H2O2) 
Dortmudt+Germany, MERCK] (3 mL 30% hydrogen 
peroxide (H2O2) + 27 mL methanol) for 15 min. Ultra V 
block (lot: PHL150128, Thermo Fischer, Fremont, CA, 
USA) was applied to the sections for 10 min prior to 
addition of the primary antibodies, which were left 
on overnight (Osteonectin (SPARC), Catalogue #:33-
5500, 1:100, Thermo Fischer, Fremont, CA, USA, Os-
teopontin monoclonal antibody 1:100, MA5-17180, 
Thermo Fischer, Fremont, CA, USA). Sections were 
washed in 3 × 5 min PBS and then incubated with 
Biotinylated Secondary Antibody (lot: PHL150128, 
Thermo Fischer, Fremont, CA, USA) for 20 min. Af-
ter washing with PBS, Streptavidin Peroxidase (lot: 
PHL150128, Thermo Fischer, Fremont, CA, USA) was 
applied to sections for 20 min. Sections were washed 
in 3 × 5 min PBS and diaminobenzidine (DAB) (lot: 
HD36221, Thermo Fischer, Fremont, CA, USA) were 
applied to sections up to 20 min. DAB was used as 
a chromogen. Control slides were prepared with the 
same procedure, without primary antibodies. Counter 
staining was done with Harris’s haematoxylin for 45 s, 
dehydrated through ascending alcohol and cleared 
in xylene (Product Number: HHS32 SIGMA, Haema-
toxylin Solution, Harris Modified, Sigma-Aldrich, 
3050 Spruce Street, Saint Louis, MO 63103, USA). 
Slides were mounted with Entellan® (lot: 107961, 
Sigma-Aldrich, St. Louis, MO, USA) and examined 
under light microscope (Nikon Eclipse 80i).
Statistical analysis
Statistics and analyses were performed using 
the SPSS 22.0 for Windows computer package pro-
gramme. In the analysis of the data, Kruskal-Wallis 
and Mann-Whitney U non-parametric statistical tests 
were used in the intergroup comparisons depending 
on the variables and the results were given as the 
mean ± standard deviation and mean rank. And, 
the results were considered statistically significant 
for p = 0 with Kruskal-Wallis test, and p < 0.05 with 
Mann-Whitney U test (Table 1).
RESULTS
Biochemical findings
It was found that oestrogen level decreased signif-
icantly in the ovariectomy group. However, it was de-
termined that oestrogen level was close to the control 
group with tamoxifen application in ovariectomised 
rats (p = 0 with Kruskal-Wallis test, p < 0.05 with 
Mann-Whitney U test). Calcium levels were statistically 
lower in the ovariectomy group as in oestrogen level. 
On the other hand, a significant increase in the calci-
um levels in the ovariectomised group with tamoxifen 
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application (p = 0 with Kruskal-Wallis test, p < 0.05 
with Mann-Whitney U test) were seen. ALP level 
was statistically higher in the ovariectomy group 
however, decreased in rats with ovariectomy and 
tamoxifen treatment (p = 0 with Kruskal-Wallis test, 
p < 0.05 with Mann-Whitney U test). The above-men-
tioned findings were shown in detail in Table 1 and 
Figure 1.
Histopathological findings
Histological examination of the tibia revealed that 
the bone lamellae were distributed regularly, and the 
osteocytes were located radially around the osteon 
structures in the control group. The Havers and Volk-
mann channels were located in parallel, the matrix 
was densely distributed, and the collagen fibres were 
irregular (Fig. 2a). Tibia bone sections of the ovariec-
Table 1. Biochemical and immunohistochemical expression data. Data are expressed as the mean ± standard deviation (SD) and 
mean rank (*p = 0 with Kruskal-Wallis test, **p < 0.05 with Mann-Whitney U test, * and ** statistically significant result)
Parameter Groups N Mean ± SD Mean rank Kruskal-Wallis 
test value
Multiple comparisons 
for groups (p < 0.05)
Oestrogen  
[mg/mL]
(1) Control
(2) Ovariectomy
(3) Ovariectomy + tamoxifen 
15
15
15
6.23 ± 0.38
1.30 ± 0.18
5.99 ± 0.19
17.6
4.50
15.3
15.825
*p = 0
(2)** 
(1)** (3)**
(2)**
Calcium  
[mg/dL]
(1) Control 
(2) Ovariectomy
(3) Ovariectomy + tamoxifen 
15
15
15
9.13 ± 0.20
6.92 ± 0.26
8.98 ± 0.20
18.1
4.50
14.8
16.226
*p = 0
(2)** 
(1)** (3)**
(2)**
Alkaline phosphatase  
[mg/dL]
(1) Control 
(2) Ovariectomy 
(3) Ovariectomy + tamoxifen 
15
15
15
27.0 ± 0.74
31.0 ± 0.75
26.0 ± 0.79
11.0
20.5
6.0
17.383
*p = 0
(2)** (3)**
(1)** (3)**
(1)** (2)**
Osteonectin (1) Control 
(2) Ovariectomy 
(3) Ovariectomy + tamoxifen 
15
15
15
3.87 ± 0.12
1.97 ± 0.26
3.91 ± 0.10
15.5
4.50
17.4
15.689
*p = 0
(2)**
(1)** (3)**
(2)**
Osteopontin (1) Control 
(2) Ovariectomy
(3) Ovariectomy + tamoxifen 
15
15
15
4.08 ± 0.31
1.67 ± 0.13
3.98 ± 0.12
16.8
4.50
16.1
15.389
*p = 0
(2)**
(1)** (3)**
(2)**
Figure 1. Biochemical and immunohistochemical expression data graphs of all groups. The quantification of osteonectin and osteopontin  
expressions: 0 — no change, 1 — too week, 2 — week, 3 — middle, 4–5 — strong (Scoring of osteonectin and osteopontin expressions 
were determined by examining histological parameters in 15 different regions within the microscope field); ALP — alkaline phosphatase.
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tomised group showed an increase in inflammatory 
cell infiltration, congestion in blood vessels and in-
creased osteoclastic cells with degenerative changes 
in the periphery of compact bone. In bone trabeculae, 
loss of osteon structures and lamellar bone structure 
and degeneration were observed (Fig. 2b). Tamox-
ifen citrate administration after ovariectomy group 
revealed, increased collagen fibres in the periphery 
of the compact bone, increased osteoblastic activity, 
progression of matrix release and osteocyte differ-
entiation decreased osteoclast cells. A significant 
maturation of osteocytes in the compact bone and 
the osteon lines in which the Havers channels were 
concentrated around the lamellar bone (Fig. 2c).
Immunohistochemical findings
In the control group sections, osteonectin expres-
sion was positive in osteoblast cells in the endosteum 
region near the bone marrow, in osteocyte cells resi-
dent of lacuna, and in Havers and Wolkmann channels 
(Fig. 3a). In the ovariectomised group, osteonectin 
expression in the collagen fibres, osteoclastic cells and 
hyperplasic osteoblast cells around the blood vessels 
located within the degenerative area was reduced in 
a positive reaction (Fig. 3b). In the tamoxifen adminis-
tered group after ovariectomy, osteonectin expression 
was positively observed in collagen fibres, increased 
osteoblast cells and osteocyte cells embedded in lacu-
na in the periphery of wide bone trabeculae (Fig. 3c).
In the control group sections, osteopontin expres-
sion was observed around the osteoblast cells in the 
periphery of the bones, the osteocytes in the lacuna 
and some of the matrix areas around the osteon 
lines (Fig. 3d). In the ovariectomised group, weak 
osteopontin expression was observed in osteoclast 
cells within degenerative area around thinned bone 
trabeculae. Weak osteopontin expression was also ob-
served in osteoblast cells and osteocyte cells of bone 
trabeculae (Fig. 3e). In the group of tamoxifen citrate 
after ovariectomy, positive osteopontin expression in 
osteoblast cells was observed in the osteocyte cells 
around the Havers and Volkmann channels (Fig. 3f).
Statistically, we found that osteopontin and os-
teonectin protein expression was decreased in the 
ovariectomised group (p = 0 with Kruskal-Wallis test, 
p < 0.05 with Mann-Whitney U test). However, os-
teonectin and osteopontin expression levels in the 
ovariectomised group and ovariectomy + tamox-
ifen group were found to be statistically significant 
(p < 0.05 with Mann-Whitney U test). The values of 
the control group supported this analysis.
DISCUSSION
Osteoporosis is defined as low bone mass and 
bone structure with high fracture risk [45]. Bone 
fragility occurs due to excessive resorption and de-
creased bone formation [8]. It is reported that oste-
oporosis affects about 25 million individuals in the 
United States alone, and it is estimated that women 
> 50 years old possess an 11–18% risk of suffering 
a hip fracture [6]. The most common form of osteo-
porosis is postmenopausal bone loss associated with 
ovarian hormone deficiency [18]. Previous studies 
have suggested that OVX reduces bone mass in rat 
models and modified micro-architecture in different 
skeletal sites containing trabecular bone [24], and 
Figure 2. a. Haematoxylin and eosin (H&E) staining (control group). Tibial bone lamellas are regular, distribution of osteocytes around osteon  
structures, the matrix dense and irregular distribution of collagen fibres can be seen; b. H&E staining (ovariectomy group). An increase  
in inflammatory cell infiltration, congestion in blood vessels (red arrow) and osteoclastic cells with degenerative changes in the periphery 
of compact bone, osteon structures loss and loss of lamellar bone structure and degeneration (yellow arrow) can be seen; c. H&E staining 
(ovariectomy +tamoxifen group). An increase in collagen fibres in the periphery of the compact bone (yellow arrow), osteoblastic activity, 
progression of matrix release and decrease in osteoclast cells can be seen. A significant maturation of osteocytes in the compact bone and 
the osteon lines (red arrow) are visible. 
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postmenopausal osteoporosis is commonly used an-
imal models [38]. Rats are commonly used in OVX 
model, as because subjects like primates that are most 
similar to human, there are limits such as high cost 
of maintenance, reduced availability in experimental 
labs, ethical permissions etc. But there is a contrary 
on the issue that use of rat models for osteoporosis is 
the lack of Haversian remodelling in the rat skeleton. 
According to Lelovas et al. (2008) [23]; in humans, 
increased Haversian remodelling is the main cause 
of cortical porosity, but rats do not have a well-de-
veloped Haversian remodelling system. On the other 
hand, ovariectomy of skeletally mature rats leads to 
a condition similar to menopause, in that the surgery 
leads to cancellous and endocortical bone loss by 
increasing the overall rate of bone remodelling and 
by altering the balance between bone formation and 
bone resorption, such that resorption predominates 
at selected skeletal sites [14].
Takayama et al. [35] also carried out that ovariec-
tomised rats exhibit the same hormonal changes as 
observed in humans with osteoporosis. It was report-
ed that the bone loss caused by ovariectomy depends 
on the degree of skeletal area and the time since ova-
riectomy. Cao et al. [4] examined the effect of icariin 
on fracture healing in an ovariectomised patient and 
reported that the use of icariin may help to improve 
fracture healing in postmenopausal osteoporosis and 
can be improved as an alternative therapy. The effect 
of oestrogen deficiency was reduced bone mass due to 
increased bone resorption and increased osteoclastic 
activity and also decreased new bone formation due 
to decreased osteoblastic life. Ovariectomy produced 
significant increases in medullary area, periosteal 
bone formation rate, and periosteal bone apposition 
rate compared to values in sham operated animals 
but, did not change endosteal bone formation rate. 
The increase in medullary area resulted from an in-
crease in osteoclast number and resorbing surface 
length. Although endosteal forming surface length 
decreased, this was compensated by an increase 
in the apposition rate. 17-b-oestradiol and tamox-
ifen each prevented the increase in bone formation 
rate and medullary area in ovariectomised rats [17]. 
Figure 3. a. Osteonectin immunostaining (control group). Positive osteonectin expression in osteoblast cells in the endosteum region near 
the bone marrow and osteocyte cells within osteon area (black arrow) can be seen; b. Osteonectin immunostaining (ovariectomy group). 
Osteonectin expression in the collagen fibres (yellow arrow), osteoclastic cells and hyperplasic osteoblast cells around the blood vessels, de-
crease in osteonectin expression within trabecular bone (red arrow) can be seen; c. Osteonectin immunostaining (ovariectomy + tamoxifen 
group). Positive osteonectin expression in osteoblast cells (yellow arrow), and osteocyte cells in the periphery of wide bone trabecular (red 
arrow) are visible; d. Osteopontin immunostaining (control group). Positive osteopontin expression around the osteoblast cells in the periphery 
of the bones, the osteocytes in the lacuna and some of the matrix areas around the osteon lines can be seen; e. Osteopontin immunostaining 
(ovariectomy group). Weak osteopontin expression in osteoclast cells around thin bone trabeculae (yellow arrow), osteoblast cells and oste-
ocyte cells of bone trabeculae (red arrow) are visible; f. Osteopontin immunostaining (ovariectomy + tamoxifen group). Positive osteopontin 
expression in osteoblast cells, osteocyte cells around the Havers channels and Volkmann channels (red arrow) can be seen. 
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Tamoxifen reduced the length of the resorbing sur-
face and osteoclast number to values observed in 
control operated animals. The findings demonstrate 
that in the rat, tamoxifen acts as an oestrogen ago-
nist by preventing the skeletal alterations that result 
from ovarian hormone deficiency [40]. In our study, 
osteonectin expression in collagen fibres and osteo-
clastic cells scattered among thinner bone trabeculae 
and osteonectin expression in osteoblast cells with 
hyperplasia was found to be decreased in the ova-
riectomised group.
In contrast to the oestrogen-antagonistic effect in 
human breast cancer, studies in rat [16, 39], confirmed 
in human [25, 37], demonstrated that tamoxifen is 
an oestrogen agonist in bone, Baloglu and Deveci [1] 
reported that clomiphene citrate administration after 
ovariectomy, it was observed that an increase in the 
number of osteoprogenitor cells and osteoblasts, 
and a decrease in the number of osteoclast cells in 
the region of the bone trabeculae. They stated that 
osteoblasts support the synthesis of bone matrix and 
the construction of bone trabeculae and bone repair. 
Bone remodelling is a constant and dynamic process 
in which osteoclasts resorb old bone and osteoblasts 
form new bone [5, 28]. Remodelling of the bone is 
a complex condition involving the proliferation of 
osteoblast cells, the formation of matrices and the 
emergence of mature bone cells and the emergence 
of bone trabeculae. Celik et al. [7] reported that oes-
trogen deficiency occurring 30 days after bilateral 
ovariectomy in adult female rats causes changes in 
bone metabolism, which is associated with a loss 
of bone mass. Wronski et al. [43] investigated the 
long-term effects of ovariectomy on proximal tibial 
metaphyseal trabecular bone histomorphometry in 
ovariectomised rats. Turner et al. [39] suggested that 
tamoxifen may have an effect on the bone micro-
scopic structure by decreases in both the number 
and activity of osteoclasts, and net loss of trabecular 
bone. Tamoxifen and oestrogen have similar actions in 
the diaphysis and metaphysis of the tibia, suggesting 
an agonist or partial agonist activity for tamoxifen 
on bone [2]. Our study showed an increase in oste-
oporosis activity after ovariectomy. Trabecular bone 
thinning and degenerative changes were observed 
and osteoclastic activity was decreased. As a result of 
tamoxifen citrate application, increased osteoblastic 
activity was found to be replaced with the degener-
ative changes induced by new bone formation and 
accelerating osteocyte development.
The osteonectin protein was localised in min-
eralised bone trabeculae and was found to be at 
a higher level in the matrix than in the bone cells. Os-
teonectin helps to connect bone mineral and collagen 
fibrils to each other. Meanwhile, oestrogens increase 
the differentiation of osteoblast cells and stimulate 
bone matrix mineralisation, arrange the expression of 
non-collagenous proteins such as type I collagen and 
osteopontin, osteocalcin, osteonectin and the like [3].
Osteonectin is a protein known to be involved in 
cell-matrix interactions and angiogenesis. Osteonectin 
inhibits cell adhesion, cell cycle, and response to specific 
growth factors. It regulates the production of extra cel-
lular matrix and matrix metalloproteinases [44].
The new vessel formation by affecting angiogen-
esis is important for normal ossification [32]. Lacin 
et al. [22] examined the effect of formaldaldehyde 
application on bone and observed a decrease in os-
teonectin expression after injury. Considering the 
association of osteonectin, a calcium-binding pro-
tein, involved in cell adhesion, it is suggested that 
osteonectin expression was increased in osteoblast 
and osteocyte cells due to tamoxifen effect which 
may stimulate the induction of bone remodelling. 
In our study, osteonectin expression was observed 
in osteoclast cells in collagen fibres around thinned 
bone trabeculae due to the effect of osteoporosis in 
ovariectomy group, whereas osteoinductive effect 
was decreased in osteoblast and osteocyte cells with 
weak osteonectin protein. In the tamoxifen group, the 
development of new bone formation was accelerated 
by osteoinductive effect due to increased osteoblastic 
activity. Osteonectin expression in osteoblast and os-
teocyte cells showed a positive reaction. Osteopontin 
has been shown to be expressed in osteoclast-me-
diated bone resorption sites, in synovial tissues of 
patients with rheumatoid arthritis, predominantly by 
fibroblastic cells and in pannus spreading regions into 
cartilage [31]. One study revealed that osteopontin 
expression was clearly observed in the periodontal 
ligament and alveolar bone in ovariectomised rats. 
The authors hypothesised that oestrogen deficiency, 
due to ovariectomy, may cause the destruction of 
periodontal ligaments [9]. In our study, osteopontin 
expression was observed in inflammatory cells in oste-
oclast cells as a result of osteoporosis change in bone 
trabecula after ovariectomy. In the tamoxifen group, 
initiation of osteocyte cells by stimulating osteoblast 
cells and increased osteopontin expression in these 
cells induced new bone formation. 
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Despite the results, there are a few limitations. It is 
a notable point whether the prevailing activity in the 
rat skeleton is modelling or remodelling. In the adult 
human skeleton, bone formation has following the 
sequence of activation–resorption–formation called 
remodelling. But, modelling is the formation and 
resorption of bone in a specific site and the process 
is activation–formation and activation–resorption. 
Proximal tibial metaphysis is seen in the rat skeleton, 
after the age of 12 months [10, 14] is remodelling but 
we used almost younger rats. However, many thera-
peutic advances in the management of osteoporosis 
were previously studied first in animal models and 
then passed to clinical practice for example; oestrogen 
administration prevented osteopenia and decreased 
bone turnover in the ovariectomised rat model, 
a very convenient  example with the skeletal effects of 
oestrogen therapy in postmenopausal women studied 
by Lelovas et al. [23]. All combined, authors gave 
the decision of OVX model in rats is an appropriate 
model for the research of osteoporosis to provide 
information for preventive or therapeutic strategies 
to treat and manage osteoporosis. 
CONCLUSIONS
Depending on the effect of tamoxifen, osteonectin 
was thought to promote bone formation by influ-
encing collagen fibres formation, extracellular matrix 
development, osteoblast differentiation and the ca-
pacity to affect osteoclast activity. It has been sug-
gested that osteopontin, the cytokine and cell bind-
ing protein, stimulates cellular signalling pathways, 
induces bone remodelling and acts in osteoporosis.
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